文献速递贫血与红细胞疾病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

小克隆阵发性睡眠性血红蛋白尿在骨髓增生异常综合征与再生障碍性贫血中的临床及预后意义

Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia.
PubMed 文献 · Leukemia · 2021-03-04

单中心大样本研究报道,高灵敏流式检测发现3085例受检者中25%存在小(<10%)及极小(<1%)阵发性睡眠性血红蛋白尿(PNH)克隆。分析其中869例骨髓增生异常综合征(MDS)和531例再生障碍性贫血(AA)患者,发现PNH克隆在AA中更常见且更大(p=0.04)。PNH克隆阳性可预测免疫抑制治疗(IST)和造血干细胞移植(HSCT)的较好疗效,并与疾病进展、白血病演化及总生存改善相关。

要点

  • AA患者PNH克隆比MDS更常见且更大(p=0.04)。
  • PNH阳性预测IST和HSCT疗效更佳,MDS和AA均如此。
  • PNH阳性者疾病进展、白血病演化风险更低,总生存更优。

核心结论

  • PNH克隆阳性(无论大小)与MDS/AA患者对IST和HSCT的较好疗效相关,并预示疾病进展和白血病演化风险更低、总生存更优。
  • 建议对AA/MDS患者系统进行PNH检测,以助预后判断和临床/实验室随访时机选择。

研究设计与样本

  • 大型单中心研究,采用高灵敏流式细胞术检测3085例患者的PNH克隆。
  • 队列中分析869例MDS和531例AA患者。

主要发现

  • PNH克隆在AA中比MDS更常见且更大(p=0.04)。
  • MDS患者中,PNH阳性者IST应答率84% vs PNH阴性44.7%(p=0.01),HSCT应答率71% vs 56.6%。
  • AA患者中,PNH阳性者IST应答率78% vs 50%(p<0.0001),HSCT应答率97% vs 77%(p=0.01)。
  • MDS患者中,PNH阳性者IPSS进展率0.6% vs 4.9%(p<0.005),白血病演化率6.8% vs 12.7%(p=0.01)。
  • AA患者中,PNH阳性者进展为MDS率2.1% vs 6.9%(p=0.01);总生存73%(95%CI 68-77) vs 51%(48-54),PNH阴性者死亡相对HR 2.37(95%CI 1.8-3.1;p<0.0001)。

临床怎么用

  • 对AA和MDS患者应系统进行高灵敏流式PNH克隆检测。
  • PNH克隆状态可用于预测IST和HSCT疗效,并辅助预后分层和随访计划制定。

局限性

  • 单中心研究,结果需多中心验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this large single-centre study, we report high prevalence (25%) of, small (<10%) and very small (<1%), paroxysmal nocturnal hemoglobinuria (PNH) clones by high-sensitive cytometry among 3085 patients tested. Given PNH association with bone marrow failures, we analyzed 869 myelodysplastic syndromes (MDS) and 531 aplastic anemia (AA) within the cohort. PNH clones were more frequent and larger in AA vs. MDS (p = 0.04). PNH clone, irrespective of size, was a good predictor of response to immunosuppressive therapy (IST) and to stem cell transplant (HSCT) (in MDS: 84% if PNH+ vs. 44.7% if PNH-, p = 0.01 for IST, and 71% if PNH+ vs. 56.6% if PNH- for HSCT; in AA: 78 vs. 50% for IST, p < 0.0001, and 97 vs. 77%, p = 0.01 for HSCT). PNH positivity had a favorable impact on disease progression (0.6% vs. 4.9% IPSS-progression in MDS, p < 0.005; and 2.1 vs. 6.9% progression to MDS in AA, p = 0.01), leukemic evolution (6.8 vs. 12.7%, p = 0.01 in MDS), and overall survival [73% (95% CI 68-77) vs. 51% (48-54), p < 0.0001], with a relative HR for mortality of 2.37 (95% CI 1.8-3.1; p < 0.0001) in PNH negative cases, both in univariate and multivariable analysis. Our data suggest systematic PNH testing in AA/MDS, as it might allow better prediction/prognostication and consequent clinical/laboratory follow-up timing.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Fattizzo B, Ireland R, Dunlop A, et al. Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia. Leukemia. 2021. PMID: 33664463. doi:10.1038/s41375-021-01190-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。